Skip to main navigation Skip to search Skip to main content

Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer

  • Kyung Min Lee
  • , Hyebin Lee
  • , Dohyun Han
  • , Woo Kyung Moon
  • , Kwangsoo Kim
  • , Hyeon Jeong Oh
  • , Jinwoo Choi
  • , Eun Hye Hwang
  • , Seong Eun Kang
  • , Seock Ah Im
  • , Kyung Hun Lee
  • , Han Suk Ryu
  • Seoul National University
  • Kangbuk Samsung Hospital
  • National Cancer Center

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology